Orforglipron Dosing & Reconstitution Guide
Dosing Protocol
Route: Oral Frequency: Once daily Dose Range: 12–45 mg oral once daily (Phase 2 tested 12, 24, 36, 45 mg)
Safety & Contraindications
Safety: Common: nausea (30-40%), vomiting (14-22%), diarrhea (16-22%), constipation — consistent with GLP-1 class but lower than danuglipron BID GI adverse events are dose-dependent and generally transient, most common during dose titration Discontinuation due to GI adverse events: approximately 10-17% across dose groups, lower than danuglipron BID
Contraindications: Personal or family history of medullary thyroid carcinoma (GLP-1 class caution); Multiple endocrine neoplasia syndrome type 2 (MEN2); Severe hepatic impairment (hepatically metabolized)
Related Research News
FDA Approves Foundayo for Weight Loss in Orforglipron News
The FDA has approved Foundayo for weight loss, according to Orforglipron news from GoodRx. This regulatory decision highlights developments in weight management options. The approval positions Foundayo as a new tool for addressing obesity.
Oral Orforglipron Maintains Weight Loss After Injectables in ATTAIN-MAINTAIN Trial
The ATTAIN-MAINTAIN trial finds that oral orforglipron helps patients maintain weight loss gained from injectable obesity drugs. This study highlights orforglipron's role in post-treatment weight control. Oral administration provides a follow-up option after injectables.
ECO 2026: ATTAIN-MAINTAIN Trial Shows Orforglipron in Sustained Weight Loss
The ATTAIN-MAINTAIN trial at ECO 2026 demonstrates orforglipron's effectiveness for sustained weight loss. This presentation highlights the drug's specific role in weight management. Findings from the trial focus on achieving and keeping weight loss over time.